ArticleAmerican journal of hematology2022

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.

Carlo Gambacorti-Passerini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.